FENC

Business Context and Reporting Period

Company: Adherex Technologies Inc. (Note: Request metadata listed "Fennec Pharmaceuticals," but the filing text identifies the registrant as Adherex Technologies Inc.)
Reporting Period: Quarterly period ended June 30, 2007 (Form 10-Q).
Business Overview: Adherex is a development-stage biopharmaceutical company focused on cancer therapeutics. It has no commercial product revenue and relies on equity financing and collaborations. Key product candidates include Eniluracil (DPD inhibitor), ADH-1 (N-cadherin antagonist), and STS (chemoprotectant for hearing loss).
Accounting Change: Effective January 1, 2007, the Company changed its primary basis of accounting from Canadian GAAP to U.S. GAAP following the loss of its foreign private issuer status.

Key Financial Metrics

Material Changes vs. Prior Period

• Liquidity Improvement: Cash and cash equivalents increased from $5.7 million at December 31, 2006, to $20.6 million at June 30, 2007. This was driven by a $25.0 million public offering of equity units completed on February 21, 2007, which yielded net proceeds of approximately $23.2 million.
• Net Loss Trend: Net loss for the three months ended June 30, 2007, decreased to $3.2 million from $3.9 million in the same period in 2006. This reduction was primarily due to delays in Eniluracil studies and reduced R&D expenditures following the completion of patient enrollment in ADH-1 studies in late 2006.
• Expense Drivers: General and Administrative (G&A) expenses increased in the quarter due to higher stock-based compensation ($1.3 million recognized in Q2 2007 vs. $0.1 million in Q2 2006). Operating cash burn increased to approximately $1.5 million per month in the first half of 2007, compared to $1.1 million in the prior year, largely due to a $1.0 million license fee payment to GSK for Eniluracil buy-back options.

Guidance, Outlook, and Risks

• Capital Requirements: Management believes current cash resources are sufficient to fund operations into the fourth quarter of 2008. Substantial additional funding will be required thereafter via equity, debt, or collaborations.
• Development Outlook:
  • Eniluracil: Phase I trials are ongoing to determine the maximum tolerated dose. Enrollment is expected to complete in the second half of 2007.
  • ADH-1: Combination trials with chemotherapy agents are advancing. Patient enrollment for the melanoma trial (with melphalan) is expected to complete in the second half of 2007.
  • STS: A randomized trial with SIOPEL is expected to begin in the second half of 2007 pending regulatory approvals.
• Key Risks:
  • Regulatory Approval: No products have received regulatory approval; clinical trials may fail or be delayed.
  • Financing: No assurance that additional capital will be available on favorable terms.
  • Collaborations: Reliance on third parties (e.g., GSK, McGill, OHSU) for licensing and clinical execution; termination of these agreements could halt development.
  • Accounting: Potential reclassification of Canadian-dollar denominated warrants as liabilities under FAS 133, which could impact future earnings volatility.

Investor Verification Checklist

• Cash Runway: Verify the accuracy of the $20.6 million cash balance and the projected burn rate of ~$1.5 million/month to confirm the Q4 2008 liquidity timeline.
• Warrant Liability: Review the impact of potential FAS 133 reclassification of CAD-denominated warrants, which could result in significant non-cash gains or losses in future periods.
• Clinical Milestones: Monitor the completion dates for Eniluracil and ADH-1 Phase I/II trials in the second half of 2007, as delays could accelerate the need for capital.
• Stock-Based Compensation: Assess the sustainability of high stock-based compensation expenses ($1.4 million in the first half of 2007) and its impact on future dilution.
• License Obligations: Confirm the status of the $1.0 million GSK license fee payment and potential future milestone payments (up to $70 million) contingent on regulatory success.